{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T16:14:01Z","timestamp":1781367241974,"version":"3.54.1"},"reference-count":79,"publisher":"Pharmaceutical Society of Japan","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biological & Pharmaceutical Bulletin","Biol. Pharm. Bull."],"published-print":{"date-parts":[[2021,9,1]]},"DOI":"10.1248\/bpb.b21-00002","type":"journal-article","created":{"date-parts":[[2021,8,31]],"date-time":"2021-08-31T22:08:18Z","timestamp":1630447698000},"page":"1174-1183","source":"Crossref","is-referenced-by-count":6,"title":["Hospital Pharmacometrics for Optimal Individual Administration of Antimicrobial Agents for Anti-methicillin-resistant <i>Staphylococcus aureus<\/i> Infected Patients"],"prefix":"10.1248","volume":"44","author":[{"given":"Yasuhiro","family":"Tsuji","sequence":"first","affiliation":[{"name":"Center for Pharmacist Education, School of Pharmacy, Nihon University"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"163","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1) Wagner JG. History of pharmacokinetics. Pharmacol. Ther.<\/i>, 12<\/b>, 537\u2013562 (1981).","DOI":"10.1016\/0163-7258(81)90097-8"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) Gobburu JVS. Pharmacometrics 2020. J. Clin. Pharmacol.<\/i>, 50<\/b> (Suppl.), 151S\u2013157S (2010).","DOI":"10.1177\/0091270010376977"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Holford N, Karlsson MO. Time for quantitative clinical pharmacology: a proposal for a pharmacometrics curriculum. Clin. Pharmacol. Ther.<\/i>, 82<\/b>, 103\u2013105 (2007).","DOI":"10.1038\/sj.clpt.6100231"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) Acar JF. Consequences of bacterial resistance to antibiotics in medical practice. Clin. Infect. Dis.<\/i>, 24<\/b> (Suppl. 1), S17\u2013S18 (1997).","DOI":"10.1093\/clinids\/24.Supplement_1.S17"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) Kollef MH. Optimizing antibiotic therapy in the intensive care unit setting. Crit. Care<\/i>, 5<\/b>, 189\u2013195 (2001).","DOI":"10.1186\/cc1022"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6) Cosgrove SE, Sakoulas G, Perencevich EN, Schwaber MJ, Karchmer AW, Carmeli Y. Comparison of mortality associated with methicillin-resistant and methicillin-susceptible Staphylococcus aureus bacteremia: a meta-analysis. Clin. Infect. Dis.<\/i>, 36<\/b>, 53\u201359 (2003).","DOI":"10.1086\/345476"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7) Cosgrove SE, Qi Y, Kaye KS, Harbarth S, Karchmer AW, Carmeli Y. The impact of methicillin resistance in Staphylococcus aureus<\/i> bacteremia on patient outcomes: mortality, length of stay, and hospital charges. Infect. Control Hosp. Epidemiol.<\/i>, 26<\/b>, 166\u2013174 (2005).","DOI":"10.1086\/502522"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8) Shorr AF, Combes A, Kollef MH, Chastre J. Methicillin-resistant Staphylococcus aureus prolongs intensive care unit stay in ventilator-associated pneumonia, despite initially appropriate antibiotic therapy. Crit. Care Med.<\/i>, 34<\/b>, 700\u2013706 (2006).","DOI":"10.1097\/01.CCM.0000201885.57697.21"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9) Takeuchi H, Matsuno N, Senuma K, et al.<\/i> Evidence of different pharmacokinetics including relationship among AUC<\/i>, peak, and trough levels between cyclosporine and tacrolimus in renal transplant recipients using new pharmacokinetic parameter\u2013why cyclosporine is monitored by C(2) level and tacrolimus by trough level. Biol. Pharm. Bull.<\/i>, 31<\/b>, 90\u201394 (2008).","DOI":"10.1248\/bpb.31.90"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10) Holford NH. Target concentration intervention: beyond Y2K. Br. J. Clin. Pharmacol.<\/i>, 48<\/b>, 9\u201313 (1999).","DOI":"10.1046\/j.1365-2125.1999.00971.x"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11) Holford N, Ma G, Metz D. TDM is dead. Long live TCI! Br. J. Clin. Pharmacol.<\/i>, bcp.14434 (2020).","DOI":"10.1111\/bcp.14434"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12) Ogasawara K. 8. Revised \u201cEthical Guidelines for Medical and Health Research Involving Human Subjects.\u201d Nihon Hoshasen Gijutsu Gakkai Zasshi<\/i>, 73<\/b>, 397\u2013402 (2017).","DOI":"10.6009\/jjrt.2017_JSRT_73.5.397"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13) Liu C, Bayer A, Cosgrove SE, Daum RS, Fridkin SK, Gorwitz RJ, Kaplan SL, Karchmer AW, Levine DP, Murray BE, Rybak MJ, Talan DA, Chambers HF. Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus<\/i> infections in adults and children. Clin. Infect. Dis.<\/i>, 52<\/b>, e18\u2013e55 (2011).","DOI":"10.1093\/cid\/ciq146"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14) Moise-Broder PA, Forrest A, Birmingham MC, Schentag JJ. Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus<\/i> lower respiratory tract infections. Clin. Pharmacokinet.<\/i>, 43<\/b>, 925\u2013942 (2004).","DOI":"10.2165\/00003088-200443130-00005"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15) Fukumori S, Tsuji Y, Mizoguchi A, Kasai H, Ishibashi T, Iwamura N, To H. Association of the clinical efficacy of vancomycin with the novel pharmacokinetic parameter area under the trough level (AUTL) in elderly patients with hospital-acquired pneumonia. J. Clin. Pharm. Ther.<\/i>, 41<\/b>, 399\u2013402 (2016).","DOI":"10.1111\/jcpt.12399"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16) Yasuhara M, Iga T, Zenda H, Okumura K, Oguma T, Yano Y, Hori R. Population pharmacokinetics of vancomycin in Japanese adult patients. Ther. Drug Monit.<\/i>, 20<\/b>, 139\u2013148 (1998).","DOI":"10.1097\/00007691-199804000-00003"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17) Yamamoto M, Kuzuya T, Baba H, Yamada K, Nabeshima T. Population pharmacokinetic analysis of vancomycin in patients with gram-positive infections and the influence of infectious disease type. J. Clin. Pharm. Ther.<\/i>, 34<\/b>, 473\u2013483 (2009).","DOI":"10.1111\/j.1365-2710.2008.01016.x"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18) Klahn P, Martinez JP, Sandoval A. Empiric vancomycin dosing in neonates: relationship between initial dose and 24\u2009h area under the curve\/minimum inhibitory concentration ratio. Rev. Chilena Infectol.<\/i>, 37<\/b>, 99\u2013105 (2020).","DOI":"10.4067\/s0716-10182020000200099"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19) Lodise TP, Patel N, Lomaestro BM, Rodvold KA, Drusano GL. Relationship between initial vancomycin concentration\u2013time profile and nephrotoxicity among hospitalized patients. Clin. Infect. Dis.<\/i>, 49<\/b>, 507\u2013514 (2009).","DOI":"10.1086\/600884"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20) Hiraki Y, Tsuji Y, Yasumori N, Nagano M, Inoue D, Kamimura H, Karube Y, Kawano F. Elevations of urinary pH may lower vancomycin serum concentration. Int. J. Clin. Pharmacol. Ther.<\/i>, 53<\/b>, 987\u2013996 (2015).","DOI":"10.5414\/CP202300"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21) Tobin CM, Lovering AM, Sweeney E, MacGowan AP. Analyses of teicoplanin concentrations from 1994 to 2006 from a U.K. assay service. J. Antimicrob. Chemother.<\/i>, 65<\/b>, 2155\u20132157 (2010).","DOI":"10.1093\/jac\/dkq266"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22) Matsumoto K, Watanabe E, Kanazawa N, Fukamizu T, Shigemi A, Yokoyama Y, Ikawa K, Morikawa N, Takeda Y. Pharmacokinetic\/pharmacodynamic analysis of teicoplanin in patients with MRSA infections. Clin. Pharmacol.<\/i>, 8<\/b>, 15\u201318 (2016).","DOI":"10.2147\/CPAA.S96143"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23) Ramos-Mart\u00edn V, Johnson A, McEntee L, Farrington N, Padmore K, Cojutti P, Pea F, Neely MN, Hope WW. Pharmacodynamics of teicoplanin against MRSA. J. Antimicrob. Chemother.<\/i>, 72<\/b>, 3382\u20133389 (2017).","DOI":"10.1093\/jac\/dkx289"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24) Carver PL, Nightingale CH, Quintiliani R, Sweeney K, Stevens RC, Maderazo E. Pharmacokinetics of single-dose and multiple-dose teicoplanin in healthy-volunteers. Antimicrob. Agents Chemother.<\/i>, 33<\/b>, 82\u201386 (1989).","DOI":"10.1128\/AAC.33.1.82"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25) Lortholary O, Tod M, Rizzo N, Padoin C, Biard O, Casassus P, Guillevin L, Petitjean O. Population pharmacokinetic study of teicoplanin in severely neutropenic patients. Antimicrob. Agents Chemother.<\/i>, 40<\/b>, 1242\u20131247 (1996).","DOI":"10.1128\/AAC.40.5.1242"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26) Soy D, Lopez E, Ribas J. Teicoplanin population pharmacokinetic analysis in hospitalized patients. Ther. Drug Monit.<\/i>, 28<\/b>, 737\u2013743 (2006).","DOI":"10.1097\/01.ftd.0000249942.14145.ff"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27) Ogawa R, Kobayashi S, Sasaki Y, Makimura M, Echizen H. Population pharmacokinetic and pharmacodynamic analyses of teicoplanin in Japanese patients with systemic MRSA infection. Int. J. Clin. Pharmacol. Ther.<\/i>, 51<\/b>, 357\u2013366 (2013).","DOI":"10.5414\/CP201739"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28) Kato H, Hamada Y, Hagihara M, Hirai J, Nishiyama N, Koizumi Y, Yamagishi Y, Matsuura K, Mikamo H. Retrospective study of teicoplanin loading regimen that rapidly achieves target 15\u201330 mu g\/mL serum trough concentration. J. Infect. Chemother.<\/i>, 22<\/b>, 308\u2013313 (2016).","DOI":"10.1016\/j.jiac.2016.01.019"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29) Zhou L, Gao Y, Cao W, Liu J, Guan H, Zhang H, Shi Y, Lv W, Cheng L. Retrospective analysis of relationships among the dose regimen, trough concentration, efficacy, and safety of teicoplanin in Chinese patients with moderate-severe Gram-positive infections. Infection and Drug Resistance<\/i>, 11<\/b>, 29\u201336 (2018).","DOI":"10.2147\/IDR.S146961"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30) Hiraki Y, Yasumori N, Nagano M, Inoue D, Tsuji Y, Kamimura H, Karube Y. Optimal loading regimen and achievement of trough concentrations for teicoplanin using Japanese population parameters. Int. J. Antimicrob. Agents<\/i>, 45<\/b>, 87\u201388 (2015).","DOI":"10.1016\/j.ijantimicag.2014.09.014"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31) Nakano T, Nakamura Y, Takata T, Irie K, Sano K, Imakyure O, Mishima K, Futagami K. Change of teicoplanin loading dose requirement for incremental increases of systemic inflammatory response syndrome score in the setting of sepsis. Int. J. Clin. Pharmacol.<\/i>, 38<\/b>, 908\u2013914 (2016).","DOI":"10.1007\/s11096-016-0308-3"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32) Matsumoto K, Kanazawa N, Ikawa K, Fukamizu T, Shigemi A, Yaji K, Shimodozono Y, Morikawa N, Takeda Y, Yamada K. Determination of teicoplanin trough concentration target and appropriate total dose during the first 3 days: a retrospective study in patients with MRSA infections. J. Infect. Chemother.<\/i>, 16<\/b>, 193\u2013199 (2010).","DOI":"10.1007\/s10156-010-0038-8"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33) Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron<\/i>, 16<\/b>, 31\u201341 (1976).","DOI":"10.1159\/000180580"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34) Filler G, Browne R, Seikaly MG. Glomerular filtration rate as a putative \u2018surrogate end-point\u2019 for renal transplant clinical trials in children. Pediatr. Transplant.<\/i>, 7<\/b>, 18\u201324 (2003).","DOI":"10.1034\/j.1399-3046.2003.00015.x"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35) Hoek FJ, Kemperman FAW, Krediet RT. A comparison between cystatin C, plasma creatinine and the Cockcroft and Gault formula for the estimation of glomerular filtration rate. Nephrol. Dial. Transplant.<\/i>, 18<\/b>, 2024\u20132031 (2003).","DOI":"10.1093\/ndt\/gfg349"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36) Larsson A, Malm J, Grubb A, Hansson LO. Calculation of glomerular filtration rate expressed in mL\/min from plasma cystatin C values in mg\/L. Scand. J. Clin. Lab. Invest.<\/i>, 64<\/b>, 25\u201330 (2004).","DOI":"10.1080\/00365510410003723"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37) Grubb A, Bjork J, Lindstrom V, Sterner G, Bondesson P, Nyman U. A cystatin C-based formula without anthropometric variables estimates glomerular filtration rate better than creatinine clearance using the Cockcroft\u2013Gault formula. Scand. J. Clin. Lab. Invest.<\/i>, 65<\/b>, 153\u2013162 (2005).","DOI":"10.1080\/00365510510013596"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38) Sjostrom P, Tidman M, Jones I. Determination of the production rate and non-renal clearance of cystatin C and estimation of the glomerular filtration rate from the serum concentration of cystatin C in humans. Scand. J. Clin. Lab. Invest.<\/i>, 65<\/b>, 111\u2013124 (2005).","DOI":"10.1080\/00365510510013523"},{"key":"39","doi-asserted-by":"crossref","unstructured":"39) Grubb A, Nyman U, Bjork J, Lindstrom V, Rippe B, Sterner G, Christensson A. Simple cystatin C-based prediction equations for glomerular filtration rate compared with the modification of diet in renal disease prediction equation for adults and the Schwartz and the Counahan\u2013Barratt prediction equations for children. Clin. Chem.<\/i>, 51<\/b>, 1420\u20131431 (2005).","DOI":"10.1373\/clinchem.2005.051557"},{"key":"40","doi-asserted-by":"crossref","unstructured":"40) Kasai H, Tsuji Y, Hiraki Y, Tsuruyama M, To H, Yamamoto Y. Population pharmacokinetics of teicoplanin in hospitalized elderly patients using cystatin C as an indicator of renal function. Journal of Infection and Chemotherapy: Official Journal of the Japan Society of Chemotherapy<\/i>, 24<\/b>, 284\u2013291 (2018).","DOI":"10.1016\/j.jiac.2017.12.002"},{"key":"41","doi-asserted-by":"crossref","unstructured":"41) McCabe RE, Remington JS. C-reactive protein in patients with bacteremia. J. Clin. Microbiol.<\/i>, 20<\/b>, 317\u2013319 (1984).","DOI":"10.1128\/jcm.20.3.317-319.1984"},{"key":"42","doi-asserted-by":"crossref","unstructured":"42) Clyne B, Olshaker JS. The C-reactive protein. J. Emerg. Med.<\/i>, 17<\/b>, 1019\u20131025 (1999).","DOI":"10.1016\/S0736-4679(99)00135-3"},{"key":"43","doi-asserted-by":"crossref","unstructured":"43) Ogami C, Tsuji Y, Muraki Y, Mizoguchi A, Okuda M, To H. Population pharmacokinetics and pharmacodynamics of teicoplanin and C-reactive protein in hospitalized patients with gram-positive infections. Clin. Pharmacol. Drug Dev.<\/i>, 9<\/b>, 175\u2013188 (2020).","DOI":"10.1002\/cpdd.684"},{"key":"44","doi-asserted-by":"crossref","unstructured":"44) Johnson A. Daptomycin in the treatment of skin, soft-tissue and invasive infections due to Gram-positive bacteria. Future Microbiol.<\/i>, 1<\/b>, 255\u2013265 (2006).","DOI":"10.2217\/17460913.1.3.255"},{"key":"45","doi-asserted-by":"crossref","unstructured":"45) Seaton RA, Menichetti F, Dalekos G, Beiras-Fernandez A, Nacinovich F, Pathan R, Hamed K. Evaluation of effectiveness and safety of high-dose daptomycin: results from patients included in the European Cubicin((R)) Outcomes Registry and Experience. Adv. Ther.<\/i>, 32<\/b>, 1192\u20131205 (2015).","DOI":"10.1007\/s12325-015-0267-4"},{"key":"46","doi-asserted-by":"crossref","unstructured":"46) Falcone M, Russo A, Venditti M, Novelli A, Pai MP. Considerations for higher doses of daptomycin in critically ill patients with methicillin-resistant Staphylococcus aureus bacteremia. Clin. Infect. Dis.<\/i>, 57<\/b>, 1568\u20131576 (2013).","DOI":"10.1093\/cid\/cit582"},{"key":"47","doi-asserted-by":"crossref","unstructured":"47) Bhavnani SM, Rubino CM, Ambrose PG, Drusano GL. Daptomycin exposure and the probability of elevations in the creatine phosphokinase level: data from a randomized trial of patients with bacteremia and endocarditis. Clin. Infect. Dis.<\/i>, 50<\/b>, 1568\u20131574 (2010).","DOI":"10.1086\/652767"},{"key":"48","doi-asserted-by":"crossref","unstructured":"48) D\u2019Costa VM, Mukhtar TA, Patel T, Koteva K, Waglechner N, Hughes DW, Wright GD, De Pascale G. Inactivation of the lipopeptide antibiotic daptomycin by hydrolytic mechanisms. Antimicrob. Agents Chemother.<\/i>, 56<\/b>, 757\u2013764 (2012).","DOI":"10.1128\/AAC.05441-11"},{"key":"49","doi-asserted-by":"crossref","unstructured":"49) Ogami C, Tsuji Y, Kasai H, Hiraki Y, Yamamoto Y, Matsunaga K, Karube Y, To H. Evaluation of pharmacokinetics and the stability of daptomycin in serum at various temperatures. Int. J. Infect. Dis.<\/i>, 57<\/b>, 38\u201343 (2017).","DOI":"10.1016\/j.ijid.2017.01.017"},{"key":"50","doi-asserted-by":"crossref","unstructured":"50) Safdar N, Andes D, Craig WA. In vivo<\/i> pharmacodynamic activity of daptomycin. Antimicrob. Agents Chemother.<\/i>, 48<\/b>, 63\u201368 (2004).","DOI":"10.1128\/AAC.48.1.63-68.2004"},{"key":"51","doi-asserted-by":"crossref","unstructured":"51) Tsukada H, Tsuji Y, Yamashina T, Tsuruta M, Hiraki Y, Tsuruyama M, Ogami C, Kawasuji H, Sakamaki I, Yamamoto Y. Pharmacokinetics and pharmacodynamics of daptomycin in a clinical setting. J. Infect. Chemother.<\/i>, 26<\/b>, 230\u2013235 (2020).","DOI":"10.1016\/j.jiac.2019.08.017"},{"key":"52","doi-asserted-by":"crossref","unstructured":"52) Kearns GL, Abdel-Rahman SM, Blumer JL, Reed MD, James LP, Jacobs RF, Bradley JA, Welshman IR, Jungbluth GL, Stalker DJ. Single dose pharmacokinetics of linezolid in infants and children. Pediatr. Infect. Dis. J.<\/i>, 19<\/b>, 1178\u20131184 (2000).","DOI":"10.1097\/00006454-200012000-00012"},{"key":"53","doi-asserted-by":"crossref","unstructured":"53) Cattaneo D, Alffenaar JW, Neely M. Drug monitoring and individual dose optimization of antimicrobial drugs: oxazolidinones. Expert Opin. Drug Metab. Toxicol.<\/i>, 12<\/b>, 533\u2013544 (2016).","DOI":"10.1517\/17425255.2016.1166204"},{"key":"54","doi-asserted-by":"crossref","unstructured":"54) Brier ME, Stalker DJ, Aronoff GR, Batts DH, Ryan KK, O\u2019Grady M, Hopkins NK, Jungbluth GL. Pharmacokinetics of linezolid in subjects with renal dysfunction. Antimicrob. Agents Chemother.<\/i>, 47<\/b>, 2775\u20132780 (2003).","DOI":"10.1128\/AAC.47.9.2775-2780.2003"},{"key":"55","doi-asserted-by":"crossref","unstructured":"55) Pea F, Cojutti PG, Baraldo M. A 10-year experience of therapeutic drug monitoring (TDM) of linezolid in a hospital-wide population of patients receiving conventional dosing: is there enough evidence for suggesting TDM in the majority of patients? Basic Clin. Pharmacol. Toxicol.<\/i>, 121<\/b>, 303\u2013308 (2017).","DOI":"10.1111\/bcpt.12797"},{"key":"56","doi-asserted-by":"crossref","unstructured":"56) Tsuji Y, Hiraki Y, Matsumoto K, Mizoguchi A, Kobayashi T, Sadoh S, Morita K, Kamimura H, Karube Y. Thrombocytopenia and anemia caused by a persistent high linezolid concentration in patients with renal dysfunction. J. Infect. Chemother.<\/i>, 17<\/b>, 70\u201375 (2011).","DOI":"10.1007\/s10156-010-0080-6"},{"key":"57","doi-asserted-by":"crossref","unstructured":"57) Tsuji Y, Hiraki Y, Matsumoto K, Mizoguchi A, Sadoh S, Kobayashi T, Takemura Y, Sakamoto S, Morita K, Kamimura H, Karube Y. Pharmacokinetics and protein binding of linezolid in cerebrospinal fluid and serum in a case of post-neurosurgical bacterial meningitis. Scand. J. Infect. Dis.<\/i>, 43<\/b>, 982\u2013985 (2011).","DOI":"10.3109\/00365548.2011.600327"},{"key":"58","doi-asserted-by":"crossref","unstructured":"58) Tsuji Y, Hiraki Y, Matsumoto K, Mizoguchi A, Sadoh S, Kobayashi T, Sakamoto S, Morita K, Yukawa E, Kamimura H, Karube Y. Evaluation of the pharmacokinetics of linezolid in an obese Japanese patient. Scand. J. Infect. Dis.<\/i>, 44<\/b>, 626\u2013629 (2012).","DOI":"10.3109\/00365548.2011.652164"},{"key":"59","doi-asserted-by":"crossref","unstructured":"59) Tsuji Y, Hashimoto W, Taniguchi S, Hiraki Y, Mizoguchi A, Yukawa E, To H. Pharmacokinetics of linezolid in the mediastinum and pleural space. Int. J. Infect. Dis.<\/i>, 17<\/b>, E1060\u2013E1061 (2013).","DOI":"10.1016\/j.ijid.2013.03.008"},{"key":"60","doi-asserted-by":"crossref","unstructured":"60) Tsuji Y, Yukawa E, Hiraki Y, Matsumoto K, Mizoguchi A, Morita K, Kamimura H, Karube Y, To H. Population pharmacokinetic analysis of linezolid in low body weight patients with renal dysfunction. J. Clin. Pharmacol.<\/i>, 53<\/b>, 967\u2013973 (2013).","DOI":"10.1002\/jcph.133"},{"key":"61","doi-asserted-by":"crossref","unstructured":"61) Tsuji Y, Tashiro M, Ashizawa N, Ota Y, Obi H, Nagura S, Narukawa M, Fukahara K, Yoshimura N, To H, Yamamoto Y. Treatment of mediastinitis due to methicillin-resistant Staphylococcus aureus<\/i> in a renal dysfunction patient undergoing adjustments to the linezolid dose. Intern. Med.<\/i>, 54<\/b>, 235\u2013239 (2015).","DOI":"10.2169\/internalmedicine.54.2292"},{"key":"62","doi-asserted-by":"crossref","unstructured":"62) Ogami C, Tsuji Y, To H, Yamamoto Y. Pharmacokinetics, toxicity and clinical efficacy of linezolid in Japanese pediatric patients. J. Infect. Chemother.<\/i>, 25<\/b>, 979\u2013986 (2019).","DOI":"10.1016\/j.jiac.2019.05.025"},{"key":"63","doi-asserted-by":"crossref","unstructured":"63) Birmingham MC, Rayner CR, Meagher AK, Flavin SM, Batts DH, Schentag JJ. Linezolid for the treatment of multidrug-resistant, gram-positive infections: experience from a compassionate-use program. Clin. Infect. Dis.<\/i>, 36<\/b>, 159\u2013168 (2003).","DOI":"10.1086\/345744"},{"key":"64","doi-asserted-by":"crossref","unstructured":"64) Sotgiu G, Centis R, D\u2019Ambrosio L, et al.<\/i> Efficacy, safety and tolerability of linezolid containing regimens in treating MDR-TB and XDR-TB: systematic review and meta-analysis. Eur. Respir. J.<\/i>, 40<\/b>, 1430\u20131442 (2012).","DOI":"10.1183\/09031936.00022912"},{"key":"65","doi-asserted-by":"crossref","unstructured":"65) Ikuta S, Tanimura K, Yasui C, Aihara T, Yoshie H, Iida H, Beppu N, Kurimoto A, Yanagi H, Mitsunobu M, Yamanaka N. Chronic liver disease increases the risk of linezolid-related thrombocytopenia in methicillin-resistant Staphylococcus aureus<\/i>-infected patients after digestive surgery. J. Infect. Chemother.<\/i>, 17<\/b>, 388\u2013391 (2011).","DOI":"10.1007\/s10156-010-0188-8"},{"key":"66","doi-asserted-by":"crossref","unstructured":"66) Takahashi Y, Takesue Y, Nakajima K, Ichiki K, Tsuchida T, Tatsumi S, Ishihara M, Ikeuchi H, Uchino M. Risk factors associated with the development of thrombocytopenia in patients who received linezolid therapy. J. Infect. Chemother.<\/i>, 17<\/b>, 382\u2013387 (2011).","DOI":"10.1007\/s10156-010-0182-1"},{"key":"67","doi-asserted-by":"crossref","unstructured":"67) Nukui Y, Hatakeyama S, Okamoto K, Yamamoto T, Hisaka A, Suzuki H, Yata N, Yotsuyanagi H, Moriya K. High plasma linezolid concentration and impaired renal function affect development of linezolid-induced thrombocytopenia. J. Antimicrob. Chemother.<\/i>, 68<\/b>, 2128\u20132133 (2013).","DOI":"10.1093\/jac\/dkt133"},{"key":"68","doi-asserted-by":"crossref","unstructured":"68) Hirano R, Sakamoto Y, Tachibana N, Ohnishi M. Retrospective analysis of the risk factors for linezolid-induced thrombocytopenia in adult Japanese patients. Int. J. Clin. Pharm.<\/i>, 36<\/b>, 795\u2013799 (2014).","DOI":"10.1007\/s11096-014-9961-6"},{"key":"69","doi-asserted-by":"crossref","unstructured":"69) Natsumoto B, Yokota K, Omata F, Furukawa K. Risk factors for linezolid-associated thrombocytopenia in adult patients. Infection<\/i>, 42<\/b>, 1007\u20131012 (2014).","DOI":"10.1007\/s15010-014-0674-5"},{"key":"70","doi-asserted-by":"crossref","unstructured":"70) Ichie T, Suzuki D, Yasui K, Takahashi H, Matsuda M, Hayashi H, Sugiura Y, Sugiyama T. The association between risk factors and time of onset for thrombocytopenia in Japanese patients receiving linezolid therapy: a retrospective analysis. J. Clin. Pharm. Ther.<\/i>, 40<\/b>, 279\u2013284 (2015).","DOI":"10.1111\/jcpt.12260"},{"key":"71","doi-asserted-by":"crossref","unstructured":"71) Kato H, Hamada Y, Hagihara M, Hirai J, Yamagishi Y, Matsuura K, Mikamo H. Bicytopenia, especially thrombocytopenia in hemodialysis and non-hemodialysis patients treated with linezolid therapy. J. Infect. Chemother.<\/i>, 21<\/b>, 707\u2013712 (2015).","DOI":"10.1016\/j.jiac.2015.06.007"},{"key":"72","doi-asserted-by":"crossref","unstructured":"72) Hanai Y, Matsuo K, Ogawa M, Higashi A, Kimura I, Hirayama S, Kosugi T, Nishizawa K, Yoshio T. A retrospective study of the risk factors for linezolid-induced thrombocytopenia and anemia. J. Infect. Chemother.<\/i>, 22<\/b>, 536\u2013542 (2016).","DOI":"10.1016\/j.jiac.2016.05.003"},{"key":"73","doi-asserted-by":"crossref","unstructured":"73) Sasaki T, Takane H, Ogawa K, Isagawa S, Hirota T, Higuchi S, Horii T, Otsubo K, Ieiri I. Population pharmacokinetic and pharmacodynamic analysis of linezolid and a hematologic side effect, thrombocytopenia, in Japanese patients. Antimicrob. Agents Chemother.<\/i>, 55<\/b>, 1867\u20131873 (2011).","DOI":"10.1128\/AAC.01185-10"},{"key":"74","doi-asserted-by":"crossref","unstructured":"74) Boak LM, Rayner CR, Grayson ML, Paterson DL, Spelman D, Khumra S, Capitano B, Forrest A, Li J, Nation RL, Bulitta JB. Clinical population pharmacokinetics and toxicodynamics of linezolid. Antimicrob. Agents Chemother.<\/i>, 58<\/b>, 2334\u20132343 (2014).","DOI":"10.1128\/AAC.01885-13"},{"key":"75","doi-asserted-by":"crossref","unstructured":"75) Bernstein WB, Trotta RF, Rector JT, Tjaden JA, Barile AJ. Mechanisms for linezolid-induced anemia and thrombocytopenia. Ann. Pharmacother.<\/i>, 37<\/b>, 517\u2013520 (2003).","DOI":"10.1345\/aph.1C361"},{"key":"76","doi-asserted-by":"crossref","unstructured":"76) Pascoalinho D, Vilas MJ, Coelho L, Moreira P. Linezolid-related immune-mediated severe thrombocytopenia. Int. J. Antimicrob. Agents<\/i>, 37<\/b>, 88\u201389 (2011).","DOI":"10.1016\/j.ijantimicag.2010.10.001"},{"key":"77","doi-asserted-by":"crossref","unstructured":"77) Tsuji Y, Holford NHG, Kasai H, Ogami C, Heo YA, Higashi Y, Mizoguchi A, To H, Yamamoto Y. Population pharmacokinetics and pharmacodynamics of linezolid-induced thrombocytopenia in hospitalized patients. Br. J. Clin. Pharmacol.<\/i>, 83<\/b>, 1758\u20131772 (2017).","DOI":"10.1111\/bcp.13262"},{"key":"78","doi-asserted-by":"crossref","unstructured":"78) Ogami C, Tsuji Y, Nishi Y, Kawasuji H, To H, Yamamoto Y. External evaluation of population pharmacokinetics and pharmacodynamics in linezolid-induced thrombocytopenia: the transferability of published models to different hospitalized patients. Ther. Drug Monit.<\/i>, 43<\/b>, 271\u2013278 (2021).","DOI":"10.1097\/FTD.0000000000000816"},{"key":"79","unstructured":"79) RStudio-Inc-Shiny. \u201cWeb Application Framework for R. R package version 0.10.1.\u201d: \u2039http:\/\/CRAN.R-project.org\/package5shiny\u203a, accessed 1 February, 2021."}],"container-title":["Biological and Pharmaceutical Bulletin"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/44\/9\/44_b21-00002\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,4]],"date-time":"2021-09-04T04:17:22Z","timestamp":1630729042000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/44\/9\/44_b21-00002\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,1]]},"references-count":79,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1248\/bpb.b21-00002","relation":{},"ISSN":["0918-6158","1347-5215"],"issn-type":[{"value":"0918-6158","type":"print"},{"value":"1347-5215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,1]]},"article-number":"b21-00002"}}